Matthias Bodenstedt, Chief Financial Officer at MoonLake Immunotherapeutics (MLTX), sold 2,426 shares at $19.56 ($47K) on 2026-04-14, disclosed to the SEC on 2026-04-16.
Scheduled sale ($47k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| MLTX | SELL | 2026-05-13 | $273K | — | Filing → |
| MLTX | SELL | 2026-04-10 | $1.7M | — | Filing → |
| MLTX | BUY | 2025-10-09 | $198K | — | Filing → |